EQA Programme 2023
Labquality’s external quality assessment programme (EQAS) is aimed at medical laboratories and point-of-care testing sites. The programme includes more than 170 clinically relevant external quality assessment schemes and it is fully compliant with ISO15189 standard requirements.
Subscription for 2023 will open 3 October 2022
Please subscribe to the 2023 EQA programmes before the end of November 2022 to ensure your participation in all needed EQA rounds. You can renew your subscription by contacting our local partner in your country. Direct customers of Labquality can renew their subscriptions on LabScala starting at 3 October 2022. If you need more information, please contact our customer service info@labquality.fi.
Changes in the 2023 program:
New schemes and products
– 2704 ACTH and cortisol
– 2706 Salivary cortisol
– 2754 Faecal elastase
– 5250 Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis
– 5261 Fungal infections, nucleic acid detection
– 5556 HSV1/HSV2/VZV/T. pallidum, nucleic acid detection
– 5965 CXCL 13 Chemokine
– 5230 Mycobacterium tuberculosis, drug resistance
– 2115 Haemoglobin, 1-level HemoCue 801 and HemoCue 301
Planned pilot schemes
Information about pilot contents and schedules will be announced later. Pilot schemes are EQA schemes under our product development.
All changes are listed in the Product Catalogue 2023 on page 5.
Please download the catalogue from the button below.
